Partial
Mostly Aligned
Patient Risk:
Medium
Summary
The AI response largely aligns with the label on key points: strong CYP3A4 inhibitors (erythromycin, clarithromycin) increase atorvastatin exposure and raise myopathy risk; rifampin induces metabolism; atorvastatin is CYP3A4-metabolized; dosing adjustments are advised with interacting agents; CK monitoring and patient reporting of muscle symptoms are supported. It overstates some effect sizes (e.g., a 4–10x increase with erythromycin) and contains at least one inconsistent item about rifampin's impact on efficacy, indicating partial alignment.
Category Scores
Accurate Statements
Erythromycin is a strong inhibitor of CYP3A4.
7.1 Strong Inhibitors of CYP 3A4; 12.3 Pharmacokinetics
Clarithromycin is a strong inhibitor of CYP3A4.
7.1 Strong Inhibitors of CYP 3A4
Erythromycin increases atorvastatin exposure.
Table 3 data in 12.3 Pharmacokinetics; text in 7.1
Clarithromycin increases atorvastatin exposure up to approximately 4.4-fold.
Table 3
Rifampin induces metabolism of atorvastatin.
Table 3; 7 Drug Interactions
Atorvastatin is metabolized by CYP3A4 in the liver.
12.3 Pharmacokinetics
Lower starting and maintenance doses should be used when taken concomitantly with interacting drugs.
5.1 Skeletal Muscle; 7 Drug Interactions
Periodic CK determinations may be considered in situations of potential myopathy risk.
5.1 Skeletal Muscle
Muscle pain or weakness signals trouble—seek care.
5.1 Skeletal Muscle
Unsupported Statements
Penicillins (amoxicillin, ampicillin) have no significant interaction with atorvastatin.
Penicillins are not discussed in the label’s interaction tables; no explicit statement about no interaction is provided.
Cephalosporins (cephalexin, cefuroxime) are generally compatible with atorvastatin.
Cephalosporins are not specifically addressed in the interaction sections; no compatibility statement is provided.
Azithromycin is low-risk when used with atorvastatin.
Azithromycin is not explicitly discussed as low-risk in the label’s interaction sections.
Fluoroquinolones (ciprofloxacin, levofloxacin) have minimal CYP3A4 effect with atorvastatin.
Label does not discuss fluoroquinolones in the interaction sections.
Tetracyclines (doxycycline) have no interaction concerns with atorvastatin.
Tetracyclines are not addressed in the label’s interaction sections.
Sulfonamides (sulfamethoxazole in Bactrim) are safe with atorvastatin, though monitor for unrelated additive effects.
Sulfonamides are not discussed in the label’s interaction sections.
Non-CYP3A4 antibiotics bypass CYP3A4 metabolism of atorvastatin.
The label does not provide a statement that non-CYP3A4 antibiotics bypass atorvastatin metabolism.
Consult your doctor or pharmacist if prescribed together.
The label provides prescribing recommendations and cautions but does not contain the exact advisory phrase.
They may switch antibiotics.
Label does not provide guidance to switch antibiotics.
No routine need for alternatives unless the combination is high-risk.
The label discusses precautions and dose adjustments but does not contain this exact advisory phrase.
Interactions are dose/duration-dependent; short courses are often fine.
The label describes dose/duration dependencies but does not provide this exact generalized statement.
Alcohol worsens statin risks regardless.
No statement regarding alcohol effects on statin interactions is present.
Contradictions
Low
AI Statement
Clarithromycin inhibits atorvastatin less severely than erythromycin.
Label Reference
7.1 Strong Inhibitors of CYP 3A4; Table 3
Low
AI Statement
Erythromycin and clarithromycin increase atorvastatin exposure 4-10x.
Label Reference
7.1 Strong Inhibitors of CYP 3A4; Table 3
Low
AI Statement
Rifampin may lower Lipitor efficacy; monitor lipids.
Label Reference
7 Drug Interactions, 12 Pharmacokinetics
Important Omissions
Explicit label statements for penicillins, cephalosporins, azithromycin, fluoroquinolones, tetracyclines, sulfonamides interactions are not present; no direct 'no interaction' claims are provided in label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Label identifies significant myopathy/rhabdomyolysis risk with certain antibiotic classes (macrolides, azoles, ritonavir-containing regimens) and need for monitoring; some claims in the AI response misstate magnitudes or applicability.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Inconsistent claim about rifampin's effect on Lipitor efficacy; overstatement of some interaction magnitudes (erythromycin).
Suggested Improvement
Correct numeric claims for erythromycin vs clarithromycin exposure; remove or temper statements implying automatic lipid-monitoring-required effects for rifampin; ensure all claims map to exact label sections (7, 7.1, 12.3, 5.1) and Table 3.